REVIEW: mRNA-Based Therapeutics – Advances and Perspectives

---

O. V. Sergeeva^1,2, V. E. Koteliansky^1,2, and T. S. Zatsepin^1,2,3*

¹Lomonosov Moscow State University, Department of Chemistry, 119991 Moscow, Russia; fax: +7 (495) 939-3181; E-mail: olga.sergeeva.v@gmail.com

²Skolkovo Institute of Science and Technology, 3 Nobel str., Skolkovo Innovation Center, 143026 Moscow, Russia; E-mail: t.zatsepin@skoltech.ru, V.Kotelianski@skoltech.ru

³Central Research Institute of Epidemiology, The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance, 111123 Moscow, Russia; E-mail: tsz@yandex.ru

^* To whom correspondence should be addressed.

Received February 29, 2016; Revision received March 27, 2016

---

In this review we discuss features of mRNA synthesis and modifications used to minimize immune response and prolong efficiency of the translation process in vivo. Considerable attention is given to the use of liposomes and nanoparticles containing lipids and polymers for the mRNA delivery. Finally we briefly discuss mRNAs which are currently in the clinical trials for cancer immunotherapy, vaccination against infectious diseases, and replacement therapy.

---

KEY WORDS: mRNA, in vivo delivery, therapy, nucleic acids, nanoparticles

DOI: 10.1134/S0006297916070075

---